Nkarta, Inc. (NASDAQ:NKTX) CEO Sells $38,231.60 in Stock

Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) CEO Paul J. Hastings sold 17,378 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the transaction, the chief executive officer now owns 319,859 shares of the company's stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Nkarta Stock Performance

Shares of NASDAQ NKTX traded down $0.02 during trading on Friday, hitting $2.47. The company had a trading volume of 1,770,362 shares, compared to its average volume of 1,352,778. Nkarta, Inc. has a 12 month low of $2.08 and a 12 month high of $16.24. The firm has a market capitalization of $174.31 million, a P/E ratio of -1.31 and a beta of 0.85. The stock has a 50 day simple moving average of $2.54 and a 200 day simple moving average of $4.21.

Analysts Set New Price Targets

NKTX has been the subject of a number of research reports. HC Wainwright lowered their price objective on Nkarta from $22.00 to $18.00 and set a "buy" rating for the company in a research report on Monday, November 11th. RODMAN&RENSHAW raised shares of Nkarta to a "strong-buy" rating in a research report on Wednesday, October 9th. Needham & Company LLC lowered their price objective on shares of Nkarta from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, November 8th. Mizuho decreased their price target on shares of Nkarta from $20.00 to $16.00 and set an "outperform" rating on the stock in a research note on Thursday, November 21st. Finally, Rodman & Renshaw assumed coverage on shares of Nkarta in a research note on Wednesday, October 9th. They set a "buy" rating and a $14.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Nkarta currently has an average rating of "Buy" and a consensus price target of $15.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH purchased a new stake in Nkarta during the 3rd quarter valued at about $33,000. GAMMA Investing LLC boosted its position in Nkarta by 110.9% during the third quarter. GAMMA Investing LLC now owns 9,972 shares of the company's stock worth $45,000 after acquiring an additional 5,243 shares during the last quarter. Forefront Analytics LLC acquired a new stake in shares of Nkarta during the 2nd quarter worth approximately $70,000. Intech Investment Management LLC purchased a new stake in shares of Nkarta in the 3rd quarter valued at approximately $74,000. Finally, SG Americas Securities LLC acquired a new position in shares of Nkarta in the third quarter valued at approximately $93,000. Hedge funds and other institutional investors own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.